For a company still defined by the pandemic-era vaccine windfall, BioNTech is about to put its oncology credentials under the microscope. Two clinical data readouts — one already released, the other days away — will either validate or undermine a transformation that has absorbed billions in research spending and reshaped the company’s entire operating structure.
The market has already started voting with its feet. BioNTech’s stock has slid 15.2% in the past 30 days to €76.30, brushing up against a 52-week low of €72.50. At one point in recent trading it dipped even lower to €75.70, underscoring the nervousness that surrounds a company in the middle of a costly strategic pivot.
The first piece of encouraging news came from BNT323, a HER2-targeting antibody-drug conjugate. In a phase-2 cohort of 145 patients with advanced HER2-positive endometrial cancer, the confirmed objective response rate reached 47.9%, with median progression-free survival of 8.1 months. The response was especially pronounced in a subgroup with high HER2 expression, where the objective response rate climbed above 70% and the median duration of response stretched to 10.3 months. BioNTech and its partner DualityBio are planning to file a regulatory application with the FDA in 2026, building on the fast-track and breakthrough therapy designations the drug received in 2023. A confirmatory global phase-3 trial is already underway.
What makes BNT323 stand out, however, is its activity across a range of HER2 levels. In patients with low HER2 expression, the response rate hit 33.9%; in those with medium expression, 40.4%. That breadth matters because the nearest competitor, Enhertu, earned accelerated FDA approval in April 2024 only for tumors with very high HER2 expression — a narrower field of play.
Attention now shifts to Pumitamig, BioNTech’s lead bispecific antibody and the centerpiece of its oncology pipeline. The drug will feature prominently at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 29 to June 2. The company is scheduled to present data from the phase-2 portion of the ROSETTA-Lung-02 trial, testing Pumitamig in combination with chemotherapy against Merck & Co.’s Keytruda plus chemotherapy in first-line non-small cell lung cancer. Keytruda is the current standard of care, and a compelling showing would not only boost Pumitamig’s prospects but also burnish BioNTech’s credibility as a serious oncology contender.
Should investors sell immediately? Or is it worth buying BioNTech?
Beyond these two candidates, BioNTech’s pipeline has expanded rapidly. The company is now running more than 25 phase-2/3 studies across 17 clinical programs, including the anti-CTLA-4 antibody Gotistobart, the bispecific BNT327, and the HER2-directed conjugate BNT323. By the end of 2026, management expects to have 15 phase-3 studies underway, with seven late-stage data readouts slated for this year alone.
Financing that ambition comes at a cost. In the first quarter, BioNTech reported revenue of €118.1 million, while its dollar-denominated filings — reflecting its U.S. listing — showed $138 million. The net loss widened to €531.9 million, or $622.3 million, driven by declining COVID-19 vaccine sales and escalating research outlays in oncology and antibody-drug conjugate programs. The company still expects full-year 2026 revenue of €2.0 billion to €2.3 billion (or $2.3 billion to $2.6 billion), a range that provides some planning visibility even as the burn rate remains high.
Yet BioNTech carries a substantial cushion. At the end of March, it held $19.6 billion in cash and equivalents, and the board has authorized the repurchase of up to $1.0 billion in American depositary shares through May 6, 2027, with the timing and volume dependent on market conditions.
Management is also taking steps to rein in operating costs. Pfizer will assume full responsibility for manufacturing the jointly marketed COVID-19 vaccine by the end of the year, freeing up capacity and reducing fixed costs tied to the vaccine business. On the manufacturing front, BioNTech plans to close three German production sites in Idar-Oberstein, Marburg, and Tübingen, affecting roughly 1,860 jobs. By 2029, the company expects annual savings of up to €500 million from these measures, with the funds redirected into its oncology pipeline.
The ASCO embargo lifts on May 21, offering a first glimpse of the Pumitamig results. By the time the conference ends on June 2, investors will have a much clearer sense of whether BioNTech’s pivot from pandemic star to cancer-fighting biotech is gaining real momentum — or still struggling to escape its own past.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from May 20 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 20.
BioNTech: Buy or sell? Read more here...
